200 mg of testosterone per week is a supraphysiologic dose. It sits roughly two to four times above the 50 to 100 mg per week that healthy adult testes produce naturally, and it typically pushes total testosterone to 900-1,500 ng/dL depending on injection interval and individual metabolism. Most men reach steady-state serum levels within 4-6 weeks of weekly injections, though symptom and safety changes unfold over months. This dose reliably suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), raises hematocrit, and changes body composition measurably within 12-20 weeks. It is a prescription dose for diagnosed hypogonadism in some protocols, not a maintenance dose.
What 200 mg Per Week Does Inside the Body
Exogenous testosterone enters the bloodstream and binds to the androgen receptor in muscle, bone, brain, and reproductive tissue. The same molecule also serves as a prohormone. About 5-7% converts to dihydrotestosterone (DHT) via 5-alpha-reductase, and roughly 0.2-0.3% aromatizes to estradiol via the aromatase enzyme. At 200 mg per week, both conversion pathways become quantitatively significant, which explains most side effects beyond the androgen effect itself.
The dose also acts on the hypothalamic-pituitary-gonadal axis. Rising serum testosterone feeds back negatively on the hypothalamus, cutting gonadotropin-releasing hormone (GnRH) output. LH and FSH fall within days, and testicular testosterone production shuts down. This is why fertility and testicular volume decline on this dose even though serum testosterone looks excellent on paper. In plain terms: the hormone looks high in the blood, but the body stops making its own.
Pharmacokinetics matter for how a 200 mg dose feels week to week. Testosterone enanthate and cypionate have elimination half-lives of roughly 4-5 days, so a once-weekly injection creates a peak around 24-48 hours post-injection and a trough just before the next dose. The peak-to-trough swing can exceed 400-500 ng/dL. Splitting the same 200 mg into two 100 mg injections every 3.5 days narrows that swing substantially, usually below 200 ng/dL, without changing the weekly total.
Blood Levels: What 200 mg Per Week Actually Produces
Dose-response data from hypogonadism trials give a usable estimate. In a landmark dose-ranging study by Bhasin and colleagues (2001, JCEM), weekly testosterone enanthate at 125 mg produced mean trough levels near 570 ng/dL, 300 mg produced about 1,340 ng/dL, and 600 mg produced roughly 2,370 ng/dL. Interpolating, 200 mg per week lands in the 900-1,100 ng/dL trough range for a typical responder. Individual variation is wide: body weight, SHBG, injection site, and assay method shift results by 20-40%.
The reference range for total testosterone is 264-916 ng/dL in most US labs, a range derived from population percentiles, not from an optimum. A dose of 200 mg per week therefore places many men above the upper reference limit at trough and well above it at peak. That is the defining feature of this dose and the reason it requires monitoring rather than casual use.
Free testosterone tells a different and often more relevant story. SHBG binds 60-70% of circulating testosterone tightly, so men with high SHBG (older men, those with liver disease, or hyperthyroid states) may run lower free testosterone even at 200 mg per week. Men with low SHBG (obesity, insulin resistance, type 2 diabetes) may run higher free levels and more estradiol conversion. Two men with identical total testosterone on the same dose can have meaningfully different free fractions.
Testosterone Dose Comparison Table
| Weekly dose | Typical trough total T | Estradiol pressure | Hematocrit rise | LH/FSH suppression | Common clinical context |
|---|---|---|---|---|---|
| 50-75 mg | 350-550 ng/dL | Low | Small (1-3 points) | Partial to full | Low-end replacement, sensitive patients |
| 100 mg | 500-700 ng/dL | Moderate | Moderate (3-5 points) | Full | Standard starting replacement dose |
| 200 mg | 900-1,100 ng/dL | High | Substantial (5-8 points) | Full and rapid | Upper-limit replacement, athletic use |
| 300 mg | 1,200-1,400 ng/dL | High to very high | Large (8-12 points) | Full | Rarely justified clinically |
The 100 versus 200 mg comparison is the most practical one. Doubling the dose does not double symptom benefit in most men, but it does roughly double estradiol production and adds a measurable hematocrit cost. The American Urological Association's 2018 guideline on testosterone therapy recommends targeting mid-normal serum levels rather than the upper end, precisely because higher doses add risk without proportional benefit in most hypogonadal men.
Timeline: What Changes and When
| Timeframe | Measurable change | What it means |
|---|---|---|
| 24-48 hours after first injection | Serum T peak, LH/FSH begin falling | Hormone is present but no tissue change yet |
| 1-2 weeks | LH and FSH fully suppressed | Endogenous production off, fertility effects start |
| 4-6 weeks | Steady-state serum levels | Blood work becomes interpretable at trough |
| 6-8 weeks | Early strength and libido changes | Neuromuscular and central effects appear first |
| 12-16 weeks | Lean mass increase, fat mass reduction begins | Body composition shift is measurable but modest |
| 20-24 weeks | Hematocrit rise becomes clinically relevant | Monitoring interval tightens |
| 6-12 months | Full body composition and bone density effects | Most of the plateau is reached by here |
The timeline follows a consistent pattern across trials: hormone levels stabilize first, then central effects (libido, mood, energy), then slow tissue effects (muscle, fat, bone). Body composition changes at 200 mg per week are real but slower than internet narratives suggest. In controlled trials, supraphysiologic testosterone at 600 mg per week produced about 6 kg of lean mass gain over 20 weeks, and the response scales roughly with dose. A 200 mg dose plausibly produces 2-3.5 kg of lean mass gain over 20 weeks in a training individual, with substantial individual variation.
Hematocrit is the change that most often forces dose adjustment. Testosterone stimulates erythropoietin and directly suppresses hepcidin, increasing red cell production. A rise of 5-8 percentage points from baseline is typical at 200 mg per week, meaning a man starting at 44% may reach 50-52% within 6-12 months. Hematocrit above 54% is the threshold at which most clinicians act, per Endocrine Society guidance, because viscosity-related risk rises above that point.
Side Effects and Edge Cases at This Dose
Erythrocytosis is the most common dose-limiting effect. It is not a side effect to ignore, and it is more frequent at 200 mg than at 100 mg per week. Men with baseline hematocrit above 50%, smokers, and those with sleep apnea are at higher risk and may need dose reduction, therapeutic phlebotomy, or both.
Estradiol elevation is expected, not abnormal. At 200 mg per week, estradiol commonly rises to 40-70 pg/mL in men, above the typical male reference range of 10-40 pg/mL. Symptoms of high estradiol (water retention, nipple sensitivity, mood changes) occur in a minority but are more likely at this dose. Aromatase inhibitor use is common in practice but not well-supported by strong trial evidence in men, and crashing estradiol carries its own harms including joint pain and libido loss.
Fertility suppression deserves its own warning. Spermatogenesis typically falls to zero or near-zero within 3-10 weeks of starting 200 mg per week. This is reversible in most men after discontinuation, but recovery can take 6-24 months, and a small proportion do not fully recover. Men who want children should not treat this dose as fertility-neutral.
Additional red flags to watch on 200 mg per week include:
- Hematocrit above 54% or a sustained rise of more than 4 points between labs
- New or worsening sleep apnea, snoring, or morning headaches
- Blood pressure rising above 140/90 mmHg consistently
- Lower-extremity swelling, chest pain, or new shortness of breath
- New or worsening acne, hair loss, or gynecomastia
- Mood instability, aggression, or new anxiety within days of injection
Cardiovascular risk at supraphysiologic doses remains an active question. The TRAVERSE trial (2023, published in NEJM) found that testosterone replacement at replacement doses in men with hypogonadism did not increase major adverse cardiac events over a median of 33 months. That trial used doses generally at replacement level, not uniformly 200 mg per week, so its reassurance does not fully extend to the supraphysiologic range. This is an area where certainty is limited and monitoring is the honest answer.
Common Misconceptions About 200 mg Per Week
The first misconception is that 200 mg is a "standard" or "average" dose. It is not. It is at or above the upper end of typical replacement dosing for most men, and many clinicians start at 80-100 mg per week and titrate upward based on labs and symptoms. The fact that a dose is commonly discussed online does not make it a standard clinical starting point.
The second misconception is that higher total testosterone means better outcomes. Dose-response curves for symptom benefit flatten well before the levels produced by 200 mg per week, while side-effect curves keep rising. Libido and mood improvements are largely achieved at mid-normal levels in hypogonadal men. Chasing peak numbers trades a modest benefit for measurable risk.
The third misconception is that aromatase inhibitors are a routine requirement at 200 mg per week. Most men tolerate the estradiol rise without intervention, and routine AI use can suppress estradiol below the range needed for bone health and libido. Estradiol is not the enemy; uncontrolled symptomatic elevation is the problem.
The fourth misconception is that stopping the dose restores normal function quickly. Post-cycle suppression of the hypothalamic-pituitary-gonadal axis can persist for weeks to months after the last injection, and recovery of natural production is not guaranteed to be prompt. This is a practical planning issue, not a moral one.
What to Actually Do at 200 mg Per Week
Establish baselines before the first injection. That means total and free testosterone, SHBG, estradiol, hematocrit, PSA in men over 40, and blood pressure. Without a baseline, later changes cannot be interpreted.
Draw trough labs, not random labs. Blood should be drawn just before the next injection, 6-8 weeks after starting, because that is when steady state is reached and the number is interpretable. Peak labs overstate exposure and lead to unnecessary dose changes.
Split the weekly dose if swings cause symptoms. Two injections of 100 mg every 3.5 days smooth the peak-to-trough range and often reduce estradiol spikes and mood variability.
Monitor hematocrit at 3 months, then every 6-12 months. Act at 54%, not at 60%. Earlier intervention is easier than late intervention.
Do not chase total testosterone above the upper reference range without a clear clinical reason. The dose is a tool, not a target. If symptoms are controlled and labs are safe at 100-150 mg, there is no evidence that 200 mg adds benefit.
Discuss fertility plans before starting. If children are possible within the treatment window, this dose is not fertility-neutral and alternatives or sperm banking should be discussed with a clinician.
Limits of the Evidence
Much of what is stated about 200 mg per week comes from pharmacokinetic modeling and dose-ranging trials in hypogonadal men, not from large trials of healthy men using this dose for performance. The TRAVERSE trial informs replacement-level safety, not supraphysiologic safety. Long-term data on men using 200 mg per week for years, particularly with concurrent aromatase inhibitor use, are thin. Anyone presenting this dose as risk-free is overstating the evidence. Anyone presenting it as reliably dangerous is also overstating it. The honest position is that the dose is well-characterized in the short term, less characterized in the long term, and requires monitoring rather than confidence.